2. Academic Validation
  3. Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

  • J Med Chem. 2016 Feb 11;59(3):841-53. doi: 10.1021/acs.jmedchem.5b00752.
Shanshan He 1,  Jingbo Xiao 2,  Andrés E Dulcey 2,  Billy Lin 1,  Adam Rolt 2,  Zongyi Hu 1,  Xin Hu 2,  Amy Q Wang 2,  Xin Xu 2,  Noel Southall 2,  Marc Ferrer 2,  Wei Zheng 2,  T Jake Liang 1,  Juan J Marugan 2
Affiliations

Affiliations

  • 1 Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , 10 Center Drive, Bethesda, Maryland 20892, United States.
  • 2 Division of Pre-Clinical Innovations, National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
PMID: 26599718 DOI: 10.1021/acs.jmedchem.5b00752
Abstract

Recently, we reported that chlorcyclizine (CCZ, Rac-2), an over-the-counter antihistamine piperazine drug, possesses in vitro and in vivo activity against hepatitis C virus. Here, we describe structure-activity relationship (SAR) efforts that resulted in the optimization of novel chlorcyclizine derivatives as anti-HCV agents. Several compounds exhibited EC50 values below 10 nM against HCV Infection, cytotoxicity selectivity indices above 2000, and showed improved in vivo pharmacokinetic properties. The optimized molecules can serve as lead preclinical candidates for the treatment of hepatitis C virus Infection and as probes to study hepatitis C virus pathogenesis and host-virus interaction.

Figures
Products